Aurobindo Pharma Limited disclosed to stock exchanges that the US Food and Drug Administration (US FDA) classified Unit-I of its wholly owned subsidiary Eugia Pharma Specialities Limited as official action indicated (OAI). The inspection occurred at the formulation manufacturing facility in Kolthur Village, Shameerpet Mandal, Ranga Reddy, Telangana, from February 16 to February 27, 2026. This facility produces active pharmaceutical ingredients (APIs) and finished dosage formulations for global markets.
The US FDA identified four observations during the inspection, though specific details of these findings were not disclosed in the regulatory filing. The classification as OAI indicates that the facility requires corrective actions to address non-compliance issues identified during the audit. Aurobindo Pharma Limited emphasized that the OAI status does not currently affect its financial performance or operational continuity, as stated in the official communication received on May 23, 2026.
The company reiterated its commitment to maintaining global quality standards across all manufacturing units. While the OAI classification may necessitate process improvements or facility upgrades, Aurobindo Pharma Limited has not reported any quantifiable financial impact or production disruptions related to this matter. The subsidiary’s operations remain unaffected, and the company continues to serve its customer base without interruption.
Regulatory compliance remains a priority for Aurobindo Pharma Limited, which operates multiple manufacturing facilities across India and international markets. The OAI classification for Eugia Pharma Unit-I aligns with the company’s proactive approach to addressing regulatory feedback. No further actions or updates regarding this classification have been communicated as of the filing date. The company will notify stakeholders if additional developments arise in the future.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.